Biomarker & Intervention Discovery

Non-Hodgkin Lymphoma (NHL)

This page lists 11 druggable gene targets, 56 approved or trial-tested drug candidates and 15 recent clinical trials for Non-Hodgkin Lymphoma (NHL), with each agent ranked by the strength of its evidence (clinical, mechanistic or correlative). Candidates include existing drugs that could be repurposed. Sources are linked so you can check every claim.

NIH funding$281MFY2025 · RCDC estimate
Funding levelWell-Funded
Spontaneous remissionIndolent NHL (follicular): spontaneous remission in 20-30% of early-stage, allowing watch-and-wait; aggressive NHL…
Best-intervention remissionDLBCL with R-CHOP: 60-70% cure rate; Pola-R-CHP (polatuzumab): 27% improvement in 2-year PFS (POLARIX); DLBCL…
Gap sizeVariable by subtype; DLBCL has genuinely curative potential; indolent NHL remains manageable but generally incurable…
Primary barrieraccess (CAR-T) + biological (indolent NHL)
Full remission profile →
Research Tracker Chronic Disease Interventions Non-Hodgkin Lymphoma (NHL)

Remission & chronicity

Spontaneous remission
Indolent NHL (follicular): spontaneous remission in 20-30% of early-stage, allowing watch-and-wait; aggressive NHL (DLBCL): rapidly lethal without treatment in weeks-months
Best-intervention remission
DLBCL with R-CHOP: 60-70% cure rate; Pola-R-CHP (polatuzumab): 27% improvement in 2-year PFS (POLARIX); DLBCL relapsed: axicabtagene ciloleucel (axi-cel) CAR-T: 40-50% long-term remission; follicular lymphoma: obinutuzumab + chemotherapy 85-90% response, durable
Gap size
Variable by subtype; DLBCL has genuinely curative potential; indolent NHL remains manageable but generally incurable with current therapy
Primary barrier
access (CAR-T) + biological (indolent NHL)
CAR-T therapy is transformative in relapsed DLBCL but manufacturing time (2-3 weeks), cost ($400K+), and centre requirements limit access; bispecific antibodies (epcoritamab, glofitamab) offer off-the-shelf alternative

Biomarker Targets & Therapeutic Agents

Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC. Agents ranked: Clinical > Mechanistic > Correlative.

BCL2 214BTK 254CD19 40CD22 64CD3E 30CD79B 3EZH2 140MS4A1 28PIK3CD 302TNFRSF8 17XPO1 151

BCL2

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
NONSTEROIDAL ANTIINFLAMMATORY DRUG ? unclear Mechanistic DGIdb
ENDOTHELIN RECEPTOR ANTAGONIST ? unclear Mechanistic DGIdb
BORTEZOMIB ? unclear Mechanistic DGIdb
DOXORUBICIN HYDROCHLORIDE ? unclear Mechanistic DGIdb
MITOXANTRONE HYDROCHLORIDE ? unclear Mechanistic DGIdb
VENETOCLAX ↓ inhibits Mechanistic DGIdb
NAVITOCLAX ↓ inhibits Mechanistic DGIdb
ISOTRETINOIN ? unclear Mechanistic DGIdb
BRENTUXIMAB VEDOTIN ? unclear Mechanistic DGIdb
OXALIPLATIN ? unclear Mechanistic DGIdb
TAZAROTENE ? unclear Mechanistic DGIdb
LISAFTOCLAX ↓ inhibits Mechanistic DGIdb
GOSSYPOL ? unclear Mechanistic 320.0 nM (Ki) DGIdb
EDARAVONE ? unclear Mechanistic DGIdb
TENIPOSIDE ? unclear Mechanistic DGIdb
DITIOCARB ? unclear Mechanistic DGIdb
CARBOPLATIN ? unclear Mechanistic DGIdb
CILENGITIDE ? unclear Mechanistic DGIdb
ESTRAMUSTINE ? unclear Mechanistic DGIdb
RECOMBINANT INTERFERON ? unclear Mechanistic DGIdb
CISPLATIN ? unclear Mechanistic DGIdb
AZD4320 ↓ inhibits Mechanistic DGIdb
PELCITOCLAX ? unclear Mechanistic DGIdb
ORAL CONTRACEPTIVE ? unclear Mechanistic DGIdb
ANG1005 ? unclear Mechanistic DGIdb
OBATOCLAX ↓ inhibits Mechanistic DGIdb
ANTI-CD19 CAR T CELLS AT101 ↓ inhibits Mechanistic DGIdb
FOSBRETABULIN DISODIUM ? unclear Mechanistic DGIdb
APG-1252-M1 ↓ inhibits Mechanistic DGIdb
SONROTOCLAX ↓ inhibits Mechanistic DGIdb
DULANERMIN ? unclear Mechanistic DGIdb
RALTITREXED ? unclear Mechanistic DGIdb
EPIRUBICIN HYDROCHLORIDE ? unclear Mechanistic DGIdb
ETOPOSIDE ? unclear Mechanistic DGIdb
MULTIDRUG RESISTANCE MODULATOR ? unclear Mechanistic DGIdb
BCL-2 INHIBITOR BCL201 ? unclear Mechanistic DGIdb
PROTUBOXEPIN A ? unclear Mechanistic DGIdb
RIBAVIRIN ? unclear Mechanistic DGIdb
DIETHYLSTILBESTROL ? unclear Mechanistic DGIdb
APRINOCARSEN ? unclear Mechanistic DGIdb

Showing top 40 of 214 agents ranked by evidence tier.

BTK

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
PRN694 ↓ inhibits Mechanistic DGIdb
RN486 ↓ inhibits Mechanistic DGIdb
PD166285 ? unclear Mechanistic DGIdb
PTD10 ↓ inhibits Mechanistic DGIdb
BRANEBRUTINIB ↓ inhibits Mechanistic DGIdb
ACALABRUTINIB ↓ inhibits Mechanistic DGIdb
COMPOUND 71 [WO2018191577A1] ↓ inhibits Mechanistic DGIdb
COMPOUND 25 [PMID: 31260299] ↓ inhibits Mechanistic DGIdb
COMPOUND 38 [PMID: 24915291] ↓ inhibits Mechanistic DGIdb
IBRUTINIB ↓ inhibits Mechanistic 0.5 nM (IC50) DGIdb
ZM447439 ? unclear Mechanistic DGIdb
BTK INHIBITOR TL-895 ? unclear Mechanistic DGIdb
ZYBT1 ↓ inhibits Mechanistic DGIdb
EVOBRUTINIB ↓ inhibits Mechanistic DGIdb
FENEBRUTINIB ↓ inhibits Mechanistic DGIdb
TOLEBRUTINIB ↓ inhibits Mechanistic DGIdb
RILZABRUTINIB ? unclear Mechanistic DGIdb
CGI1746 ↓ inhibits Mechanistic DGIdb
TAMATINIB ? unclear Mechanistic DGIdb
ZANUBRUTINIB ↓ inhibits Mechanistic DGIdb
ENTRECTINIB ? unclear Mechanistic 158.49 nM (Ki) DGIdb
LUXEPTINIB ↓ inhibits Mechanistic DGIdb
BTK INHIBITOR 16 [PMID: 30122225] ↓ inhibits Mechanistic DGIdb
ZELEBRUDOMIDE ? unclear Mechanistic DGIdb
BIIB068 ↓ inhibits Mechanistic DGIdb
PROTAC 23 [PMID: 38321747] ↓ inhibits Mechanistic DGIdb
NVP-TAE684 ? unclear Mechanistic DGIdb
COMPOUND 36 [PMID: 21958547] ↓ inhibits Mechanistic DGIdb
CINSEBRUTINIB ↓ inhibits Mechanistic DGIdb
COMPOUND 9 [PMID: 26006010] ↓ inhibits Mechanistic DGIdb
DASATINIB ANHYDROUS ? unclear Mechanistic DGIdb
NEMTABRUTINIB ? unclear Mechanistic DGIdb
JNJ-64264681 ↓ inhibits Mechanistic DGIdb
SPEBRUTINIB ↓ inhibits Mechanistic DGIdb
CHEMBL:CHEMBL1997335 ? unclear Mechanistic DGIdb
RITLECITINIB ↓ inhibits Mechanistic DGIdb
BIRELENTINIB ↓ inhibits Mechanistic DGIdb
PF-562271 ? unclear Mechanistic DGIdb
ORELABRUTINIB ↓ inhibits Mechanistic DGIdb
MIDOBRUTINIB ↓ inhibits Mechanistic DGIdb

Showing top 40 of 254 agents ranked by evidence tier.

CD19

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
AUTOLOGOUS ANTI-CD19 CAR T-CELLS IM19 ? unclear Mechanistic DGIdb
BLINATUMOMAB ? unclear Mechanistic DGIdb
LONCASTUXIMAB TESIRINE ~ modulates Mechanistic DGIdb
AUTOLOGOUS CD19CAR-CD28-CD137/CD27/CD3ZETA-ICASP9-EXPRESSING T-LYMPHOCYTES ? unclear Mechanistic DGIdb
TISAGENLECLEUCEL ? unclear Mechanistic DGIdb
AUTOLOGOUS ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR T-CELLS C-CAR011 ? unclear Mechanistic DGIdb
VADACABTAGENE LERALEUCEL ? unclear Mechanistic DGIdb
LISOCABTAGENE MARALEUCEL ? unclear Mechanistic DGIdb
AUTOLOGOUS ANTI-CD19CAR-4-1BB-CD3ZETA-EGFRT-EXPRESSING T LYMPHOCYTES ? unclear Mechanistic DGIdb
MDX-1342 ~ modulates Mechanistic DGIdb
AXICABTAGENE CILOLEUCEL ? unclear Mechanistic DGIdb
ANTI-CD19 CAR T CELLS PREPARATION ? unclear Mechanistic DGIdb
INEBILIZUMAB ? unclear Mechanistic DGIdb
ALLOGENEIC ANTI-CD19-CAR-CD28-IL-15-EXPRESSING NATURAL KILLER T-CELLS ? unclear Mechanistic DGIdb
AZERCABTAGENE ZAPRELEUCEL ? unclear Mechanistic DGIdb
TAFASITAMAB ? unclear Mechanistic DGIdb
DENINTUZUMAB MAFODOTIN ~ modulates Mechanistic DGIdb
COLTUXIMAB RAVTANSINE ? unclear Mechanistic DGIdb
OBEXELIMAB ↓ inhibits Mechanistic DGIdb
AMG-729 ~ modulates Mechanistic DGIdb
CD19CAR-CD3ZETA-4-1BB-EXPRESSING ALLOGENEIC T-LYMPHOCYTE CELLS ? unclear Mechanistic DGIdb
AUTOLOGOUS ANTI-CD19 CAR-T CELLS TBI-1501 ? unclear Mechanistic DGIdb
AUTOLOGOUS CD19 CAR-EXPRESSING CD4+/CD8+ T-CELLS MB-CART19.1 ? unclear Mechanistic DGIdb
AFM-11 ? unclear Mechanistic DGIdb
BREXUCABTAGENE AUTOLEUCEL ~ modulates Mechanistic DGIdb
TAPLITUMOMAB PAPTOX ~ modulates Mechanistic DGIdb
ANTI-CD19 CAR T-CELLS XLCART001 ? unclear Mechanistic DGIdb
AUTOLOGOUS ANTI-CD19 CAR-EXPRESSING T-LYMPHOCYTES CLIC-1901 ? unclear Mechanistic DGIdb
DENINTUZUMAB ~ modulates Mechanistic DGIdb
AUTO3 ? unclear Mechanistic DGIdb
DEGLYCOSYLATED RICIN A CHAIN-CONJUGATED ANTI-CD19/ANTI-CD22 IMMUNOTOXINS ? unclear Mechanistic DGIdb
DUVORTUXIZUMAB ? unclear Mechanistic DGIdb
ANTI-CD19 CAR-T CELLS ? unclear Mechanistic DGIdb
AUTOLOGOUS ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR T-CELLS SJCAR19 ? unclear Mechanistic DGIdb
ONCOLYSIN B ~ modulates Mechanistic DGIdb
ANTI-CD20 CAR T CELLS PREPARATION ? unclear Mechanistic DGIdb
CD19-TARGETED CAR T2 CELLS ? unclear Mechanistic DGIdb
OBECABTAGENE AUTOLEUCEL ~ modulates Mechanistic DGIdb
JCAR014 ? unclear Mechanistic DGIdb
RELMACABTAGENE AUTOLEUCEL ? unclear Mechanistic DGIdb

CD22

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
OSPA LIPOPROTEIN ? unclear Mechanistic DGIdb
INOTUZUMAB ~ modulates Mechanistic DGIdb
AUTO3 ? unclear Mechanistic DGIdb
EPRATUZUMAB-CYS-TESIRINE ~ modulates Mechanistic DGIdb
ANTI-CD22 CAR T CELLS PREPARATION ? unclear Mechanistic DGIdb
PINATUZUMAB VEDOTIN ~ modulates Mechanistic DGIdb
BL22 ~ modulates Mechanistic DGIdb
IMMUNOTOXIN ? unclear Mechanistic DGIdb
YTTRIUM Y 90 EPRATUZUMAB ~ modulates Mechanistic DGIdb
MONO-DGA-RFB4 ~ modulates Mechanistic DGIdb
EPRATUZUMAB ↓ inhibits Mechanistic DGIdb
BECTUMOMAB ? unclear Mechanistic DGIdb
MOXETUMOMAB PASUDOTOX ~ modulates Mechanistic DGIdb
EPRATUZUMAB 90Y ~ modulates Mechanistic DGIdb
INOTUZUMAB OZOGAMICIN ~ modulates Mechanistic DGIdb
ANTI-CD22 CAR-EXPRESSING T LYMPHOCYTES ? unclear Mechanistic DGIdb
DEGLYCOSYLATED RICIN A CHAIN-CONJUGATED ANTI-CD19/ANTI-CD22 IMMUNOTOXINS ? unclear Mechanistic DGIdb
YTTRIUM Y 90 EPRATUZUMAB TETRAXETAN ↓ inhibits Mechanistic DGIdb
IMMURAIT-LL2 ~ modulates Mechanistic DGIdb
CHEMBL451045 ↓ inhibits Mechanistic 45000.0 nM (IC50) ChEMBL
CHEMBL460576 ↓ inhibits Mechanistic 9830.0 nM (IC50) ChEMBL
CHEMBL504222 ↓ inhibits Mechanistic 1760.0 nM (IC50) ChEMBL
CHEMBL511111 ↓ inhibits Mechanistic 230.0 nM (IC50) ChEMBL
CHEMBL505326 ↓ inhibits Mechanistic 1730.0 nM (IC50) ChEMBL
CHEMBL500461 ↓ inhibits Mechanistic 7480.0 nM (IC50) ChEMBL
CHEMBL504353 ↓ inhibits Mechanistic 43000.0 nM (IC50) ChEMBL
CHEMBL502862 ↓ inhibits Mechanistic 240.0 nM (IC50) ChEMBL
CHEMBL448298 ↓ inhibits Mechanistic 6220.0 nM (IC50) ChEMBL
CHEMBL453397 ↓ inhibits Mechanistic 5480.0 nM (IC50) ChEMBL
CHEMBL509633 ↓ inhibits Mechanistic 470.0 nM (IC50) ChEMBL
CHEMBL442728 ↓ inhibits Mechanistic 37700.0 nM (IC50) ChEMBL
CHEMBL450770 ↓ inhibits Mechanistic 24760.0 nM (IC50) ChEMBL
CHEMBL446730 ↓ inhibits Mechanistic 4300.0 nM (IC50) ChEMBL
CHEMBL501599 ↓ inhibits Mechanistic 900.0 nM (IC50) ChEMBL
CHEMBL473316 ↓ inhibits Mechanistic 73250.0 nM (IC50) ChEMBL
CHEMBL508909 ↓ inhibits Mechanistic 7130.0 nM (IC50) ChEMBL
CHEMBL509768 ↓ inhibits Mechanistic 400.0 nM (IC50) ChEMBL
CHEMBL502788 ↓ inhibits Mechanistic 1000.0 nM (IC50) ChEMBL
CHEMBL451427 ↓ inhibits Mechanistic 3700.0 nM (IC50) ChEMBL
CHEMBL503830 ↓ inhibits Mechanistic 1100.0 nM (IC50) ChEMBL

Showing top 40 of 64 agents ranked by evidence tier.

CD3E

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
PF-07062119 ? unclear Mechanistic DGIdb
MUROMONAB-CD3 ↓ inhibits Mechanistic DGIdb
ZWB67 ? unclear Mechanistic DGIdb
EPCORITAMAB ~ modulates Mechanistic DGIdb
OTELIXIZUMAB ? unclear Mechanistic DGIdb
SOLITOMAB ? unclear Mechanistic DGIdb
TEPODITAMAB ? unclear Mechanistic DGIdb
FORALUMAB ↓ inhibits Mechanistic DGIdb
HOKT3 ↓ inhibits Mechanistic DGIdb
LINVOSELTAMAB ? unclear Mechanistic DGIdb
TEPLIZUMAB ? unclear Mechanistic DGIdb
TARLATAMAB ? unclear Mechanistic DGIdb
BLINATUMOMAB ? unclear Mechanistic DGIdb
ERTUMAXOMAB ? unclear Mechanistic DGIdb
XALURITAMIG ? unclear Mechanistic DGIdb
RESIMMUNE ~ modulates Mechanistic DGIdb
ANTI-CD3 MONOCLONAL ANTIBODY ? unclear Mechanistic DGIdb
MEDI-565 ~ modulates Mechanistic DGIdb
MOSUNETUZUMAB ? unclear Mechanistic DGIdb
VISILIZUMAB ↓ inhibits Mechanistic DGIdb
TECLISTAMAB ~ modulates Mechanistic DGIdb
IMC-GP100 ~ modulates Mechanistic DGIdb
TALQUETAMAB ~ modulates Mechanistic DGIdb
ELRANATAMAB ~ modulates Mechanistic DGIdb
FLOTETUZUMAB ~ modulates Mechanistic DGIdb
CATUMAXOMAB ~ modulates Mechanistic DGIdb
ODRONEXTAMAB ~ modulates Mechanistic DGIdb
FBT-A05 ~ modulates Mechanistic DGIdb
GLOFITAMAB ~ modulates Mechanistic DGIdb
AX-024 ? unclear Mechanistic DGIdb

CD79B

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
POLATUZUMAB VEDOTIN ? unclear Mechanistic DGIdb
MGD-010 ? unclear Mechanistic DGIdb
CHEMBL5630968 ↓ inhibits Mechanistic 97.0 nM (Ki) ChEMBL

EZH2

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
GSK126 ↓ inhibits Mechanistic DGIdb
EPZ011989 ↓ inhibits Mechanistic DGIdb
EI1 ↓ inhibits Mechanistic DGIdb
TAZEMETOSTAT HYDROBROMIDE ↓ inhibits Mechanistic DGIdb
UNC1999 ↓ inhibits Mechanistic DGIdb
TAZEMETOSTAT ↓ inhibits Mechanistic 2.5 nM (Ki) DGIdb
EBI-2511 ↓ inhibits Mechanistic DGIdb
VALEMETOSTAT ↓ inhibits Mechanistic DGIdb
COMPOUND 15A [PMID: 36642961] ↓ inhibits Mechanistic DGIdb
EPZ005687 ↓ inhibits Mechanistic DGIdb
MEVROMETOSTAT ↓ inhibits Mechanistic DGIdb
JQEZ5 ↓ inhibits Mechanistic DGIdb
ZEPRUMETOSTAT ↓ inhibits Mechanistic DGIdb
SKLB-03220 ↓ inhibits Mechanistic DGIdb
CPI-1205 ↓ inhibits Mechanistic DGIdb
GSK343 ↓ inhibits Mechanistic DGIdb
CHEMBL:CHEMBL4545488 ? unclear Mechanistic DGIdb
TULMIMETOSTAT ↓ inhibits Mechanistic DGIdb
GSK2816126 ? unclear Mechanistic 0.5 nM (Ki) Open Targets
CHEMBL2204995 ↓ inhibits Mechanistic 2900.0 nM (IC50) ChEMBL
CHEMBL2204998 ↓ inhibits Mechanistic 4500.0 nM (IC50) ChEMBL
CHEMBL2204996 ↓ inhibits Mechanistic 1995.0 nM (IC50) ChEMBL
CHEMBL2204997 ↓ inhibits Mechanistic 79.0 nM (IC50) ChEMBL
CHEMBL2204999 ↓ inhibits Mechanistic 2510.0 nM (IC50) ChEMBL
CHEMBL1608462 ↓ inhibits Mechanistic 10632.0 nM (IC50) ChEMBL
CHEMBL3264749 ↓ inhibits Mechanistic 51000.0 nM (IC50) ChEMBL
CHEMBL3264750 ↓ inhibits Mechanistic 48000.0 nM (IC50) ChEMBL
CHEMBL3264752 ↓ inhibits Mechanistic 33000.0 nM (IC50) ChEMBL
CHEMBL3264755 ↓ inhibits Mechanistic 57000.0 nM (IC50) ChEMBL
CHEMBL3264762 ↓ inhibits Mechanistic 48000.0 nM (IC50) ChEMBL
CHEMBL3264763 ↓ inhibits Mechanistic 61000.0 nM (IC50) ChEMBL
CHEMBL3264765 ↓ inhibits Mechanistic 29000.0 nM (IC50) ChEMBL
CHEMBL3264766 ↓ inhibits Mechanistic 59000.0 nM (IC50) ChEMBL
CHEMBL3264767 ↓ inhibits Mechanistic 3600.0 nM (IC50) ChEMBL
CHEMBL3264768 ↓ inhibits Mechanistic 7900.0 nM (IC50) ChEMBL
CHEMBL3264769 ↓ inhibits Mechanistic 19000.0 nM (IC50) ChEMBL
CHEMBL3264770 ↓ inhibits Mechanistic 3400.0 nM (IC50) ChEMBL
CHEMBL3264771 ↓ inhibits Mechanistic 15000.0 nM (IC50) ChEMBL
CHEMBL3264772 ↓ inhibits Mechanistic 37000.0 nM (IC50) ChEMBL
CHEMBL3264774 ↓ inhibits Mechanistic 840.0 nM (IC50) ChEMBL

Showing top 40 of 140 agents ranked by evidence tier.

MS4A1

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
RITUXIMAB ~ modulates Mechanistic DGIdb
UBLITUXIMAB ~ modulates Mechanistic DGIdb
VELTUZUMAB ? unclear Mechanistic DGIdb
OFATUMUMAB ~ modulates Mechanistic DGIdb
OBINUTUZUMAB ~ modulates Mechanistic DGIdb
OCARATUZUMAB ~ modulates Mechanistic DGIdb
TOSITUMOMAB ~ modulates Mechanistic DGIdb
TISAGENLECLEUCEL ? unclear Mechanistic DGIdb
IODINE-131-TOSITUMOMAB ? unclear Mechanistic DGIdb
EPCORITAMAB ? unclear Mechanistic DGIdb
GLOFITAMAB ~ modulates Mechanistic DGIdb
TRU-015 ~ modulates Mechanistic DGIdb
ODRONEXTAMAB ? unclear Mechanistic DGIdb
OCRELIZUMAB ~ modulates Mechanistic DGIdb
ANTI-CD20 CAR T CELLS PREPARATION ? unclear Mechanistic DGIdb
DI-LEU16-IL2 ? unclear Mechanistic DGIdb
MONOCLONAL ANTIBODY 1F5 ? unclear Mechanistic DGIdb
MT-3724 ~ modulates Mechanistic DGIdb
MOSUNETUZUMAB ? unclear Mechanistic DGIdb
PLAMOTAMAB ? unclear Mechanistic DGIdb
AUTOLOGOUS ANTI-CD20 CAR TRANSDUCED CD4/CD8 ENRICHED T-CELLS MB-CART20.1 ? unclear Mechanistic DGIdb
FBT-A05 ~ modulates Mechanistic DGIdb
YTTRIUM Y 90 IBRITUMOMAB TIUXETAN ~ modulates Mechanistic DGIdb
BSAB (CD89-CD20) ? unclear Mechanistic DGIdb
LFB-R603 ~ modulates Mechanistic DGIdb
DIVOZILIMAB ? unclear Mechanistic DGIdb
IBRITUMOMAB TIUXETAN ? unclear Mechanistic DGIdb
TOSITUMOMAB 131I ~ modulates Mechanistic DGIdb

PIK3CD

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
PF-04691502 ↓ inhibits Mechanistic DGIdb
COMPOUND 27 [PMID: 35834807] ↓ inhibits Mechanistic DGIdb
AMDIZALISIB ↓ inhibits Mechanistic DGIdb
SAMOTOLISIB ↓ inhibits Mechanistic DGIdb
GEDATOLISIB ↓ inhibits Mechanistic 6.0 nM (IC50) DGIdb
FIMEPINOSTAT ↓ inhibits Mechanistic DGIdb
PICTILISIB ↓ inhibits Mechanistic 3.0 nM (IC50) DGIdb
DEZAPELISIB ↓ inhibits Mechanistic DGIdb
BGT-226 ↓ inhibits Mechanistic DGIdb
OMIPALISIB ↓ inhibits Mechanistic DGIdb
DACTOLISIB ↓ inhibits Mechanistic DGIdb
DUVELISIB ↓ inhibits Mechanistic DGIdb
LENIOLISIB ↓ inhibits Mechanistic DGIdb
RECILISIB ↓ inhibits Mechanistic DGIdb
STK16-IN-1 ↓ inhibits Mechanistic DGIdb
LENIOLISIB PHOSPHATE ↓ inhibits Mechanistic DGIdb
AMG-319 ↓ inhibits Mechanistic DGIdb
TGX-221 ↓ inhibits Mechanistic DGIdb
SF1126 ↓ inhibits Mechanistic DGIdb
PANULISIB ↓ inhibits Mechanistic DGIdb
GSK2636771 ↓ inhibits Mechanistic DGIdb
IDELALISIB ↓ inhibits Mechanistic DGIdb
NVP-CLR457 ↓ inhibits Mechanistic DGIdb
VOXTALISIB ↓ inhibits Mechanistic DGIdb
UMBRALISIB TOSYLATE ↓ inhibits Mechanistic DGIdb
WORTMANNIN ↓ inhibits Mechanistic 9.0 nM (IC50) DGIdb
IZORLISIB ↓ inhibits Mechanistic DGIdb
PWT-33587 ↓ inhibits Mechanistic DGIdb
CH-5132799 ? unclear Mechanistic DGIdb
AZD8186 ↓ inhibits Mechanistic DGIdb
PAXALISIB ↓ inhibits Mechanistic DGIdb
APITOLISIB ↓ inhibits Mechanistic DGIdb
COMPOUND 15A [PMID: 32069401] ↓ inhibits Mechanistic DGIdb
5-QUINOXALIN-6-YLMETHYLENE-THIAZOLIDINE-2,4-DIONE ↓ inhibits Mechanistic DGIdb
BUPARLISIB ↓ inhibits Mechanistic DGIdb
NEMIRALISIB ↓ inhibits Mechanistic DGIdb
PUQUITINIB MESYLATE DIHYDRATE ↓ inhibits Mechanistic DGIdb
AMG319 ↓ inhibits Mechanistic DGIdb
TASELISIB ↓ inhibits Mechanistic DGIdb
PARSACLISIB ↓ inhibits Mechanistic DGIdb

Showing top 40 of 302 agents ranked by evidence tier.

TNFRSF8

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
ANTI-CD30 MONOCLONAL ANTIBODY MDX-1401 ? unclear Mechanistic DGIdb
HEFI-1 ~ modulates Mechanistic DGIdb
ANTI-CD30 CAR T CELLS PREPARATION ? unclear Mechanistic DGIdb
CD30 LIGAND ? unclear Mechanistic DGIdb
IRATUMUMAB ? unclear Mechanistic DGIdb
BRENTUXIMAB VEDOTIN ~ modulates Mechanistic DGIdb
FLUTICASONE ? unclear Mechanistic DGIdb
BRENTUXIMAB ? unclear Mechanistic DGIdb
VITAMIN A COMPOUND ? unclear Mechanistic DGIdb
DACTINOMYCIN ? unclear Mechanistic DGIdb
RECOMBINANT CHEMOKINE ? unclear Mechanistic DGIdb
AUTOLOGOUS CD30CAR-CD28-CD3ZETA-EXPRESSING T-LYMPHOCYTES ? unclear Mechanistic DGIdb
AUTOLOGOUS CCR4-CD30CAR-CD28-CD3ZETA-EXPRESSING T-LYMPHOCYTES ? unclear Mechanistic DGIdb
TAFASITAMAB ? unclear Mechanistic DGIdb
AFM13 ? unclear Mechanistic DGIdb
XMAB-2513 ? unclear Mechanistic DGIdb
SGN-30 ↑ activates Mechanistic DGIdb

XPO1

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
VERDINEXOR ↓ inhibits Mechanistic 24.0 nM (EC50) DGIdb
SELINEXOR ↓ inhibits Mechanistic 18.74 nM (Kd) DGIdb
ELTANEXOR ↓ inhibits Mechanistic DGIdb
LEPTOMYCIN B ↓ inhibits Mechanistic 1.0 nM (IC50) DGIdb
FELEZONEXOR ? unclear Mechanistic DGIdb
GONIOTHALAMIN ? unclear Mechanistic DGIdb
RIFAMPIN ? unclear Mechanistic DGIdb
OSTHOLE ? unclear Mechanistic 1600.0 nM (IC50) DGIdb
CHEMBL1084286 ↓ inhibits Mechanistic 6400.0 nM (IC50) ChEMBL
CHEMBL3929869 ↓ inhibits Mechanistic 1000.0 nM (IC50) ChEMBL
CHEMBL3891836 ↓ inhibits Mechanistic 1000.0 nM (IC50) ChEMBL
CHEMBL3964319 ↓ inhibits Mechanistic 1000.0 nM (IC50) ChEMBL
CHEMBL3896208 ↓ inhibits Mechanistic 1000.0 nM (IC50) ChEMBL
CHEMBL3899053 ↓ inhibits Mechanistic 1000.0 nM (IC50) ChEMBL
CHEMBL3951325 ↓ inhibits Mechanistic 1000.0 nM (IC50) ChEMBL
CHEMBL3929349 ↓ inhibits Mechanistic 1000.0 nM (IC50) ChEMBL
CHEMBL3919410 ↓ inhibits Mechanistic 1000.0 nM (IC50) ChEMBL
CHEMBL3895766 ↓ inhibits Mechanistic 1000.0 nM (IC50) ChEMBL
CHEMBL3893042 ↓ inhibits Mechanistic 1000.0 nM (IC50) ChEMBL
CHEMBL3911673 ↓ inhibits Mechanistic 1000.0 nM (IC50) ChEMBL
CHEMBL3911830 ↓ inhibits Mechanistic 1000.0 nM (IC50) ChEMBL
CHEMBL3914451 ↓ inhibits Mechanistic 1000.0 nM (IC50) ChEMBL
CHEMBL3890257 ↓ inhibits Mechanistic 1000.0 nM (IC50) ChEMBL
CHEMBL3928302 ↓ inhibits Mechanistic 1000.0 nM (IC50) ChEMBL
CHEMBL3925662 ↓ inhibits Mechanistic 1000.0 nM (IC50) ChEMBL
CHEMBL3898004 ↓ inhibits Mechanistic 1000.0 nM (IC50) ChEMBL
CHEMBL3908175 ↓ inhibits Mechanistic 1000.0 nM (IC50) ChEMBL
CHEMBL3915859 ↓ inhibits Mechanistic 1000.0 nM (IC50) ChEMBL
CHEMBL3956187 ↓ inhibits Mechanistic 1000.0 nM (IC50) ChEMBL
CHEMBL3904126 ↓ inhibits Mechanistic 1000.0 nM (IC50) ChEMBL
CHEMBL4088268 ↓ inhibits Mechanistic 10.0 nM (IC50) ChEMBL
CHEMBL4077955 ↓ inhibits Mechanistic 25.0 nM (IC50) ChEMBL
CHEMBL4277221 ↑ activates Mechanistic 900.0 nM (EC50) ChEMBL
CHEMBL4293588 ↑ activates Mechanistic 1800.0 nM (EC50) ChEMBL
CHEMBL4278766 ↑ activates Mechanistic 3800.0 nM (EC50) ChEMBL
CHEMBL4282126 ↑ activates Mechanistic 1800.0 nM (EC50) ChEMBL
CHEMBL4283174 ↑ activates Mechanistic 900.0 nM (EC50) ChEMBL
CHEMBL4294538 ↑ activates Mechanistic 30000.0 nM (EC50) ChEMBL
CHEMBL4294903 ↑ activates Mechanistic 30000.0 nM (EC50) ChEMBL
CHEMBL4280077 ↑ activates Mechanistic 15000.0 nM (EC50) ChEMBL

Showing top 40 of 151 agents ranked by evidence tier.

Clinical Trials

Drug, biologic and supplement trials (treatment or prevention) from ClinicalTrials.gov whose main condition is Non-Hodgkin Lymphoma (NHL): recruiting, active or completed, most recently updated first. Data retrieved 2026-10-28.

A Prospective Clinical Study of CD3-CD20 Bisspecific Antibody Based Therapy Combined With CD19-CAR T Cells in the Treatment of Relapsed Refractory B-cell Non-Hodgkin Lymphoma Active Not Recruiting
NCT06464185 Phase: 1/2 Started: 2024-05-27

The aim of this study was to analyze the safety and efficacy of CD3-CD20 bispecific antibody-based therapy in combination with CD19-CAR-T cells for the treatment of relapsed and refractory B-cell Non-Hodgkin's （B-NHL） lymphoma. The main questions it aims to answer： 1. The safety of CD3-CD20 bispecif...

KSV01 Injection for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma Recruiting
NCT07260812 Phase: 1 Started: 2025-09-01

This is a single center, single arm, open-label, dose escalation, phase 1 study to evaluate the safety, tolerability and preliminary efficacy of KSV01 Injection for patients with diffuse large B-cell lymphoma.

Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma Active Not Recruiting
NCT02520791 Phase: 1 Started: 2016-09-13

This phase I trial studies the side effects and best dose of anti-inducible T-cell co-stimulator (ICOS) monoclonal antibody MEDI-570 in treating patients with peripheral T-cell lymphoma follicular variant or angioimmunoblastic T-cell lymphoma that has returned after a period of improvement (relapsed...

Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma Recruiting
NCT04545762 Phase: 1 Started: 2020-09-11

This study will assess safety and feasibility of infusing genetically modified autologous T cells transduced to express a chimeric antigen receptor targeting the B cell surface antigen Cluster of Differentiation 19 (CD19).

CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies Recruiting
NCT05442515 Phase: 1/2 Started: 2022-12-28

Background: Acute lymphoblastic leukemia (ALL) is the most common cancer in children. About 90% of children and young adults who are treated for ALL can now be cured. But if the disease comes back, the survival rate drops to less than 50%. Better treatments are needed for ALL relapses. Objective: To...

A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas Recruiting
NCT06090539 Phase: 1/2 Started: 2023-12-29

The purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary biological and clinical activity of BMS-986458, a bifunctional cereblon-dependent ligand-directed degrader of B-cell lymphoma 6 (BCL6), as a single agent and in combination with anti-lymphoma agents in pa...

Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma Recruiting
NCT07097363 Phase: 2 Started: 2025-12-07

This phase II trial tests the safety, best dose, and effectiveness of epcoritamab when given with etoposide, cyclophosphamide, vincristine, doxorubicin, prednisone and rituximab (EPOCH-R) for the treatment of patients with aggressive B-cell non-Hodgkin lymphoma. Epcoritamab is a bispecific antibody ...

Bispecific Antibody-Based Holding/Bridging Therapy Before CAR-T in Aggressive B-Cell Lymphomas Recruiting
NCT07883135 Phase: 2 Started: 2026-09

This prospective, single-center, open-label study evaluates a short course of CD20×CD3 bispecific antibody-based holding or bridging therapy before CD19-directed CAR T-cell therapy in adults with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. Participants will receive a CD20×CD3 bisp...

CAR T-cell Therapy in Patients With Renal Dysfunction Recruiting
NCT05909059 Phase: 2 Started: 2024-11-18

This is a prospective, descriptive study designed to assess the feasibility of administering CAR T therapy among patients with moderate to severe renal impairment using dose adjusted lymphodepleting chemotherapy.

Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL Recruiting
NCT06526793 Phase: 2 Started: 2024-11-27

This is a Phase 2 global, multi-center, open-label study to assess the efficacy, safety and tolerability of surovatamig (AZD0486) monotherapy in adult participants with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL) who have received at least two prior lines of therapies. The study has 2 Modu...

A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma Recruiting
NCT07123454 Phase: 1/2 Started: 2025-09-24

This is a Phase I/II open-label, global multicenter study to evaluate the safety and efficacy of AZD4512 monotherapy or in combination with other anticancer agent(s), in participants with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (B-NHL).

CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma Recruiting
NCT06026319 Phase: 1 Started: 2023-10-26

This research study involves the study of CD79b-19 CAR T cells for treating people with relapsed/refractory Non-Hodgkin Lymphoma and to understand the side effects when treated with CD79b-19 CAR T cells. This research study involves the study drugs: * CD79b-19 CAR T cells * Fludarabine and Cyclophos...

A Study of ARC-02 in B-cell NHL Recruiting
NCT07691606 Phase: 1 Started: 2026-06-22

This study is to assess safety, tolerability, pharmacokinetics (PK), pharmacodynamic (PD), and preliminary efficacy of ARC-02.

Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma Recruiting
NCT07283679 Phase: 1/2 Started: 2026-02-24

The goal of this clinical research study is to learn if ONC-PluReceptor NK cell therapy (combined with the monoclonal antibody therapies epcoritamab and tafasitamab) can help to control relapsed or refractory B-cell Non-Hodgkin Lymphoma. The safety of this treatment will also be studied.

Study of GI001 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and B-Cell Acute Lymphoblastic Leukemia Recruiting
NCT07862010 Phase: Early 1 Started: 2025-11-28

This is an open-label, multi-cohort, investigator-initiated clinical study designed to evaluate the safety, tolerability, and preliminary efficacy of GI001 in adult patients with relapsed or refractory B-cell Non-Hodgkin Lymphoma (R/R B-NHL) and B-cell Acute Lymphoblastic Leukemia (R/R B-ALL). GI001...

Agents Found By Disease-Level Search

Searched directly from “Non-Hodgkin Lymphoma (NHL)” via ClinicalTrials.gov interventions and Open Targets' disease→drug data — independent of the 11-gene target panel above. This surfaces agents whose mechanism doesn't route through a curated gene (combination therapies, standard-of-care drugs, targets outside the panel).

56 agents shown (approved or with trial evidence) — 43 not found by the gene-target search above.

Rituximab

Approved · 18 trials · source: ClinicalTrials.gov, Open Targets
NCT05848765 NCT00193492 NCT01992653

cyclophosphamideNOT in gene-target list

Phase 3 · 16 trials · source: ClinicalTrials.gov, Open Targets
NCT00005867 NCT00621452 NCT00003116

PrednisoneNOT in gene-target list

Phase 3 · 8 trials · source: ClinicalTrials.gov, Open Targets
NCT05848765 NCT01992653 NCT00842595

Vincristine

Phase 3 · 6 trials · source: ClinicalTrials.gov, Open Targets
NCT05848765 NCT00556127 NCT00187122

dexamethasoneNOT in gene-target list

Phase 3 · 6 trials · source: ClinicalTrials.gov, Open Targets
NCT00433537 NCT00556127 NCT00187122

Linperlisib combined with CPT regimenNOT in gene-target list

· 6 trials · source: ClinicalTrials.gov
NCT07195799 NCT07195799 NCT07195799

etoposide

Phase 3 · 5 trials · source: ClinicalTrials.gov, Open Targets
NCT00005867 NCT00244946 NCT00556127

Obinutuzumab

Phase 2 · 4 trials · source: ClinicalTrials.gov, Open Targets
NCT05848765 NCT01992653 NCT02987400

DoxorubicinNOT in gene-target list

Phase 3 · 4 trials · source: ClinicalTrials.gov, Open Targets
NCT05848765 NCT01992653 NCT03719105

PembrolizumabNOT in gene-target list

Phase 2 · 4 trials · source: ClinicalTrials.gov, Open Targets
NCT01953692 NCT07283822 NCT03240211

MelphalanNOT in gene-target list

Approved · 4 trials · source: ClinicalTrials.gov, Open Targets
NCT04473911 NCT00556127 NCT00244946

cytarabineNOT in gene-target list

Phase 3 · 4 trials · source: ClinicalTrials.gov, Open Targets
NCT00244946 NCT00187122 NCT01399372

methotrexateNOT in gene-target list

Approved · 4 trials · source: ClinicalTrials.gov, Open Targets
NCT00005854 NCT00187122 NCT01399372

LenalidomideNOT in gene-target list

Phase 3 · 3 trials · source: ClinicalTrials.gov, Open Targets
NCT05222555 NCT05848765 NCT01650701

doxorubicin hydrochloride

Approved · 3 trials · source: ClinicalTrials.gov, Open Targets
NCT00005867 NCT00433537 NCT04323956

prednisoloneNOT in gene-target list

Phase 3 · 3 trials · source: ClinicalTrials.gov, Open Targets
NCT00005867 NCT00971763 NCT01992653

vincristine sulfateNOT in gene-target list

Phase 3 · 3 trials · source: ClinicalTrials.gov, Open Targets
NCT00005867 NCT00971763 NCT04323956

Polatuzumab Vedotin

Phase 2 · 3 trials · source: ClinicalTrials.gov, Open Targets
NCT01992653 NCT04323956 NCT04594798

ifosfamideNOT in gene-target list

Phase 3 · 3 trials · source: ClinicalTrials.gov, Open Targets
NCT00842595 NCT03719105 NCT06905509

IBRUTINIB

Phase 3 · 3 trials · source: ClinicalTrials.gov, Open Targets
NCT02682641 NCT01325701 NCT01646021

SB-743921NOT in gene-target list

Phase 1/2 · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT00343564 NCT00343564

Epcoritamab

Phase 2 · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT05848765 NCT06905509

BendamustineNOT in gene-target list

Phase 3 · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT05848765 NCT03602157

therapeutic autologous lymphocytesNOT in gene-target list

· 2 trials · source: ClinicalTrials.gov
NCT00621452 NCT00244946

filgrastimNOT in gene-target list

Phase 3 · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT00003116 NCT00433537

cyclosporineNOT in gene-target list

Phase 2 · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT00003116 NCT00005854

fludarabine phosphateNOT in gene-target list

Phase 2 · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT01658319 NCT00856388

FLUDARABINENOT in gene-target list

Phase 3 · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT04473911 NCT03602157

MitoxantroneNOT in gene-target list

Phase 3 · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT00842595 NCT00556127

Acalabrutinib

Phase 2 · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT05004064 NCT02328014

pegfilgrastimNOT in gene-target list

Phase 3 · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT00433537 NCT04323956

paclitaxelNOT in gene-target list

Phase 2 · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT00004105 NCT00891072

Blinatumomab

Phase 2/3 · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT07153796 NCT03114865

Cyclophosphamide, Vincristine, Cytarabine, Doxorubincin, PrednisoneNOT in gene-target list

· 2 trials · source: ClinicalTrials.gov
NCT07168980 NCT07168980

carboplatin

Phase 3 · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT00891072 NCT06905509

Glofitamab + ObinutuzumabNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06867536

Tafasitamab

Phase 2 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT05222555

bleomycin sulfateNOT in gene-target list

Phase 1/2 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT00005867

CHOP regimenNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00005867

mitoxantrone hydrochloride

Phase 2 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT00005867

NSAIDNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01789216

GabapentinoidsNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01789216

Investigation agent 2NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05848765

Investigation agent 3NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05848765

Chi Lob 7/4 (A chimeric monoclonal antibody)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01561911

rituximab (GP2013)NOT in gene-target list

Approved · 1 trial · source: ClinicalTrials.gov
NCT01933516

aldesleukinNOT in gene-target list

Phase 3 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT00621452

polymerase chain reactionNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00621452

gene rearrangement analysisNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00621452

genetically engineered lymphocyte therapyNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00621452

bone marrow aspirationNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00621452

BevacizumabNOT in gene-target list

Phase 3 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT00193492

ixabepiloneNOT in gene-target list

Phase 2 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT00006221

EverolimusNOT in gene-target list

Phase 2 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT00702052

Routine Blood Draw - Phase 1 onlyNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06224309

busulfanNOT in gene-target list

Phase 3 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT00003116

Generated by the Open Source Medicine Foundation Biomarker Pipeline — 2026-10-08. Data sources: DGIdb, Open Targets, ChEMBL, PubMed, ClinicalTrials.gov. Not medical advice.